يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Taal, Walter"', وقت الاستعلام: 1.51s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

    المؤلفون: Taal, Walter1, Oosterkamp, Hendrika M.2, Walenkamp, Annemiek M. E.3, Dubbink, Hendrikus J.4, Beerepoot, Laurens V.5, Hanse, Monique C. J.6, Buter, Jan7, Honkoop, Aafke H.8, Boerman, Dolf9, de Vos, Filip Y. F.10, Dinjens, Winand N. M.4, Enting, Roelien H.11, Taphoorn, Martin J. B.12, van den Berkmortel, Franchette W. P. J.13, Jansen, Rob L. H.14, Brandsma, Dieta15, Bromberg, Jacoline E. C.1, van Heuvel, Irene1, Vernhout, René M.16, van der Holt, Bronno16

    المصدر: Lancet Oncology. Aug2014, Vol. 15 Issue 9, p943-953. 11p.

    مصطلحات موضوعية: *BEVACIZUMAB, *GLIOBLASTOMA multiforme, *RANDOMIZED controlled trials, *CANCER chemotherapy, *HYPERTENSION, *CONTROL groups, *PATIENTS


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Bevacizumab alone or in combination with chemotherapy in glioblastomas?–Authors' reply.

    المؤلفون: van den Bent, Martin J1 m.vandenbent@erasmusmc.nl, Taal, Walter1

    المصدر: Lancet Oncology. Oct2014, Vol. 15 Issue 11, pe473-e474. 1p.

    مصطلحات موضوعية: *BEVACIZUMAB, *CANCER chemotherapy, *GLIOBLASTOMA multiforme treatment, *ONCOLOGY research, *ANTINEOPLASTIC agents


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

    المؤلفون: van den Bent, Martin J.1 m.vandenbent@erasmusmc.nl, Baumert, Brigitta2,3,4,5, Erridge, Sara C.6, Vogelbaum, Michael A.7,8, Nowak, Anna K.9,10,11, Sanson, Marc12, Brandes, Alba Ariela13, Clement, Paul M.14,15, Baurain, Jean Francais16, Mason, Warren P.17, Wheeler, Helen18,19, Chinot, Olivier L.20, Gill, Sanjeev21, Griffin, Matthew22, Brachman, David G.23, Taal, Walter1, Rudà, Roberta24, Weller, Michael25, McBain, Catherine26, Reijneveld, Jaap27,28,29

    المصدر: Lancet. 10/7/2017, Vol. 390 Issue 10103, p1645-1653. 9p.

    مصطلحات موضوعية: *TEMOZOLOMIDE, *GLIOMAS, *CANCER chemotherapy, *RADIOTHERAPY, *SURVIVAL analysis (Biometry)

    الشركة/الكيان: WORLD Health Organization


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.

    المؤلفون: Erdem-Eraslan, Lale1, van den Bent, Martin J.1, Hoogstrate, Youri2,3, Naz-Khan, Hina3, Stubbs, Andrew3, van der Spek, Peter3, Böttcher, René2, Ya Gao1, de Wit, Maurice1, Taal, Walter1, Oosterkamp, Hendrika M.2,4, Walenkamp, Annemiek2,5, Beerepoot, Laurens V.2,6, Hanse, Monique C. J.7, Buter, Jan8, Honkoop, Aafke H.9, van der Holt, Bronno10, Vernhout, René M.10, Sillevis Smitt, Peter A. E.1, Kros, Johan M.11

    المصدر: Cancer Research. 2/1/2016, Vol. 76 Issue 3, p525-534. 11p.

    مصطلحات موضوعية: *GLIOBLASTOMA multiforme treatment, *CANCER relapse, *BEVACIZUMAB, *THERAPEUTIC use of monoclonal antibodies, *CANCER chemotherapy, *GENE expression

    النص الكامل

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث